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To select the sensitive anticancer agents for the treatment 
of patients with carcinoma, chemosensitivity should be 
timely assessed from biopsy specimen for patients with 
gastric carcinoma. 
 Histogram of DNA analysis from biopsy specimens 
revealed the disappearance of GZM accumulation in reflec-
tion of effects of anticancer drugs prior to the appearance 
of clinical signs. 
 In conclusion, DNA analysis from biopsy specimens is 
of great value in assessing the efficacy of anticancer drugs 
in the course of drug treatment and also in knowing the 
drug sensitivity to the tumor timely.
Material and Methods 
Endoscopic and roentgenologic examinations had been 
done before, during and after administration of anticancer 
drugs to assess the efficacy of anticancer drugs in combi-
nation with DNA analysis from biopsied specimens. The 
comparison of radiologic and endoscopic findings with the 
efficacy of anticancer drugs was made at each examination. 
 DNA analysis was conducted from biopsied speciments. 
Briefly, two or three biopsied specimens were made, add-
ing 0.1% triton x-100 and micing with scissors, and were 
filtered through a 50mcm nylon mesh and stained with 
propidium Iodide (final concentration 50mcg/ml). 
 Cellular DNA content was measured by FACS scan IV.
Introduction 
Needless to say, it seems reasonable to consider that selec-
tion of anticancer drugs should be limited to a sensitive 
drug to malignant tumors. 
 There are many methods to assess the drug sensitivity in 
vivo and vitro study. However, at present, there is nothing 
of an ideal approach to determine the drug sensitivity 
precisely as well as to assess the efficacy of anticancer 
drugs in the course of drug treatment. 
 In this preliminary study, nuclear DNA determination 
from biopsy specimens was applied for assessment of 
biologic behavior in malignant tumors and the efficacy of 
anticancer drugs in comparison with DNA analysis be-
tween prior to or after administration of anticancer drugs. 
  On the other hand, long survivals of advanced cancer are 
only few in number in spite of the development of anti-
cancer drugs. And also precise prediction of effects of 
potent anticancer drugs has to await development of the 
useful sensitivity test to anticancer drugs. 
 The purpose of this preliminary study is to certify the 
clinical application of cytometric DNA analysis for the 
assesment of the anticancer drug sensitivity from biopsied 
specimens.
Case report 
Case 1: 62 years old, male 
He complained of weightloss and dysphagia. He had a 
diagnosis of gastric cancer with Virchow' metastasis. 
Biopsy specimen of cervical nodes revealed poorly differ-
entiated adenocarcinoma. ETP (THP-ADM 30mg/m2 day 1, 
CDDP 40mg/m2 day 2, 8, Etoposide 100mg/m2 day 4, 5, 6) 
treatment was initiated at an interval of 4 weeks. Finally 
this treatment had been repeated twice. The values of 
CA19-9 (U/ml) and CEA (ng/ml) were gradually reduced, 
in particular, CA19-9 value fell to almost half of the 
pre-treatment values. 
 Roentgenologic finding was not improved as compared 
with those before and 1 month after anticancer drugs of 
ETP as shown in Fig. 1 (on the left). And also endoscopic 
finding failed to substantiate the efficacy of anticancer 
drugs (Fig. 1 on the right). 
 Meanwhile, a histogram of DNA content showed disap-
pearance of G2M accumulation as compared with that 
before administration of anticancer drugs as shown in Fig. 
2. The effect of ETP treatment for poorly differentiated 
adenocarcinoma was represented as the disappearance of 
GZM accumulation on histogram.
Fig. 1. Roentgenologic and endoscopic findings prior to and one 
month after ETP treatment
Case 2: 63 years old, male 
He complained of anemia and dysphagia. He had carci-
noma of the stomach (scirrhus type) from the cardia to the 
antrum with ascitic fluid as shown in Fig. 3. Histology 
revealed poorly differentiated adenocarcinoma. 
 At laparotomy, it was defined that carcinoma of the 
stomach involved directly the pancreas, the duodenum and 
the transverse colon with diffuse peritoneal dissemination 
(P3). Therefore, gastrectomy was abandoned. Continuous 
hyperthermic peritoneal perfusion therapy was performed 
for 50 minutes with a 42 °C saline of 3000m1 to 4000m1, 
which contained CDDP (300mg) and etoposide (300mg). 
  After the 2nd month of the treatment, roentgenologic and 
endoscopic findings were not changed as shown in Fig. 3, 
and thereafter these were no altered 3 and 4 months after 
treatment as shown in Fig. 4. DNA histograms from biopsy 
specimens of gastric lesion were shown in Fig. 5. When 
compared with that prior to the treatment, accumulation of 
G,M was already reduced on day 3 after the treatment in 
spite of a presence of the GZM phase under magnification. 
Thereafter, DNA histogram showed the appearance of GZM 
accumulation 3 months later, although it failed to be found
Fig. 2. Histogram one month after ETP treatment revealed 
disappearance of G,M accumulation as compared with that before 
ETP treatment (upper)
Fig. 3. Roentgenologic and endoscopic findings prior to and after 
continuous hyperthermic peritoneal perfusion (CHPP)
until 2 months after the treatment as shown in Fig. 5.
Fig. 4. Roentgenologic and endoscopic findings 3 and 4 months 
after CHPP. During these periods, no significant improvement 
was indicated
Fig. 5. Histogram revealed disappearance of G2M accumulation 
on day 3 after CHPP in spite of the remaining G2M accumulation 
under a magnification. At two months after CHPP, a G2M accu-
mulation was no longer seen on histogram but at three months 
after CHPP a phase of G2M accumulation was appeared again.
Discussion 
It is considered that the effect of anticancer drug should be 
predicted in case of the maximum uptake into the tumorous 
tissues. However, there have been few reports as to wheth-
er or not the drug concentration directly provides the influ-
ence of anticancer effects.'' 
 Recently, flow cytometric DNA analysis was widely 
used for assessment of nuclear DNA content in a short 
time. The efficacy of drugs used should be determined by 
the following factors and methods such as the drug concen-
tration of tissues," the degree of cellular degeneration," 
inhibition rate of TS activity,') changes in the cell cycle by 
flow cytometry5' and chemosensitivity test by SDP and 
SRC.'' 
 The advantages toward DNA analysis by flow cytometry 
are that 1) changes in the same sites are able to be serially 
observed, 2) changes in DNA synthesis are able to certify 
even though histologic alteration failed to be elucidated, 3) 
small sample size is sufficient to evaluate changes in DNA 
synthesis. 
 The cellular DNA content reflects indirectly the number 
of chromosoms, and the DNA content in malignant tumors 
increases remarkably. It is caused by amplification of 
oncogens, increasing number of chromosoms, multipolar 
mitosis, polymorphism of oncogenic structure in cell 
growth and shift of the cell line. 
  Biopsy specimens are able to obtain timely in the course 
of the treatment of anticancer drugs. DNA histogram from 
biopsy specimens showed the disapperance of G2M accu-
mulation in reflection of inhibition of DNA synthesis by 
anticancer agents."' It is suggested that drug sensitivity to 
the tumor be first indicated on changes in the peak of the 
G2M phase by anticancer agents of which the effects influ-
ence a pattern of G2M accumulation. 
  Needless to say, the more the effects of anticancer drugs 
are enhanced, the more DNA synthesis should be inhibited. 
There are reports concerning no differences in the drug 
sensitivity between diploidy and aneuploidy patterns. On 
the other hand, it has been documented that aneuploid 
tumors are more sensitive to anticancer drugs in renal cell 
carcinomas or ovary carcinomas. 
  In fact, it is accepted that radiation therapy is effective 
for aneuploid tumors. In this series, the drug sensitivity has 
been shown as the result of the disappearance of G2M 
accumulation on histogram. It implies that anticancer drugs 
sensitive to the tumors effectively act on aneuploid cells of 
malignant tumors. As a result, DNA ploidy patterns vary 
from aneuploidy to diploidy pattern because of the remain-
ing diploidy cell group.
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